Stock ZVRA ZEVRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
4.65 USD -1.48% Intraday chart for Zevra Therapeutics, Inc. 0.00% -29.01%
Jun. 04 Zevra Therapeutics Files $350 Million Mixed-Shelf; Shares Fall After Hours MT
Jun. 03 Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia At Sleep 2024 Annual Meeting CI

Evolution of the average Target Price on Zevra Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

252f4005.p8AXKT54b9kXluo8ZKDAUi8qRnU1GHfQghUKek6z1Bg.4PR6Tls_CZJR_4Z6KO2uFV5AIR9_Xhukt1lAOzfGtWn-k31tBk47vU3G3g~8378c2560dc825551f1d7788c19ea1fe

Analyst Recommendations on Zevra Therapeutics, Inc.

William Blair Starts Zevra Therapeutics With Outperform Rating MT
HC Wainwright Adjusts Price Target on Zevra Therapeutics to $15 From $10, Keeps Buy Rating MT
Canaccord Genuity Adjusts Price Target on Zevra Therapeutics to $20 From $19, Keeps Buy Rating MT
Maxim Starts Zevra Therapeutics at Buy With $12 Price Target MT
Cantor Fitzgerald Starts KemPharm at Overweight With $20 Price Target MT
KemPharm Shares Rise After Canaccord Genuity Initiates Coverage MT
Canaccord Genuity Starts KemPharm at Buy With $20 Price Target MT
HC Wainwright Cuts KemPharm's Price Target to $10 From $11, Reiterates Buy Rating MT
HC Wainwright Upgrades KemPharm to Buy From Neutral, Adjusts Price Target to $11 From $10 MT
KEMPHARM : HC Wainwright Adjusts Price Target on KemPharm to $10 From $12, Maintains Neutral Rating MT
KEMPHARM : HC Wainwright Downgrades KemPharm to Neutral From Buy, Adjusts Price Target to $12 From $24 MT
KEMPHARM : Roth Capital Starts KemPharm at Buy With $28 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.65 USD
Average target price
19 USD
Spread / Average Target
+308.60%
High Price Target
24 USD
Spread / Highest target
+416.13%
Low Price Target
15 USD
Spread / Lowest Target
+222.58%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Zevra Therapeutics, Inc.

William Blair & Co.
HC Wainwright
Canaccord Genuity
Maxim
Cantor Fitzgerald
Roth Capital Partners

Ratings for Zevra Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ZVRA Stock
  4. Consensus Zevra Therapeutics, Inc.